KURA
NASDAQ · Biotechnology
Kura Oncology Inc
$7.27
+0.47 (+6.91%)
Financial Highlights (FY 2026)
Revenue
48.55M
Net Income
-200,489,661
Gross Margin
99.9%
Profit Margin
-413.0%
Rev Growth
—
D/E Ratio
0.06
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 99.9% | 56.8% | 56.8% | 56.8% |
| Operating Margin | -449.9% | 21.2% | 23.8% | 19.3% |
| Profit Margin | -413.0% | 14.6% | 17.9% | 18.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 48.55M | 146.41M | 142.51M | 137.24M |
| Gross Profit | 48.51M | 83.09M | 80.88M | 77.89M |
| Operating Income | -218,453,757 | 31.11M | 33.93M | 26.49M |
| Net Income | -200,489,661 | 21.31M | 25.50M | 25.40M |
| Gross Margin | 99.9% | 56.8% | 56.8% | 56.8% |
| Operating Margin | -449.9% | 21.2% | 23.8% | 19.3% |
| Profit Margin | -413.0% | 14.6% | 17.9% | 18.5% |
| Rev Growth | — | -6.0% | +22.0% | -9.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 17.10M | 192.12M | 161.82M | 186.45M |
| Total Equity | 306.49M | 502.37M | 476.57M | 529.75M |
| D/E Ratio | 0.06 | 0.38 | 0.34 | 0.35 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -217,703,866 | 41.90M | 41.44M | 41.75M |
| Free Cash Flow | — | 24.20M | 22.28M | 20.94M |